Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

SLC6A3 Polymorphism Predisposes to Dopamine Overdose in Parkinson's Disease.

Robertson BD, Al Jaja AS, MacDonald AA, Hiebert NM, Tamjeedi R, Seergobin KN, Schwarz UI, Kim RB, MacDonald PA.

Front Neurol. 2018 Aug 21;9:693. doi: 10.3389/fneur.2018.00693. eCollection 2018.

2.

Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.

MacDonald AA, Monchi O, Seergobin KN, Ganjavi H, Tamjeedi R, MacDonald PA.

Mov Disord. 2013 Feb;28(2):153-60. doi: 10.1002/mds.25152. Epub 2012 Nov 19.

PMID:
23165957
3.

Differential effects of Parkinson's disease and dopamine replacement on memory encoding and retrieval.

MacDonald AA, Seergobin KN, Owen AM, Tamjeedi R, Monchi O, Ganjavi H, MacDonald PA.

PLoS One. 2013 Sep 26;8(9):e74044. doi: 10.1371/journal.pone.0074044. eCollection 2013.

4.

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group.

Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23.

5.

Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.

Proença MB, Dombrowski PA, Da Cunha C, Fischer L, Ferraz AC, Lima MM.

Neuropharmacology. 2014 Jan;76 Pt A:118-26. doi: 10.1016/j.neuropharm.2013.08.024. Epub 2013 Sep 4.

PMID:
24012539
6.
7.

Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.

van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J.

J Nucl Med. 2005 May;46(5):745-51.

8.

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease.

Habak C, Noreau A, Nagano-Saito A, Mejía-Constaín B, Degroot C, Strafella AP, Chouinard S, Lafontaine AL, Rouleau GA, Monchi O.

Brain. 2014 Nov;137(Pt 11):3025-35. doi: 10.1093/brain/awu251. Epub 2014 Sep 10.

9.

Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.

Kelada SN, Costa-Mallen P, Checkoway H, Carlson CS, Weller TS, Swanson PD, Franklin GM, Longstreth WT Jr, Afsharinejad Z, Costa LG.

Pharmacogenet Genomics. 2005 Sep;15(9):659-68.

PMID:
16041244
10.

Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion.

Ilango A, Kesner AJ, Keller KL, Stuber GD, Bonci A, Ikemoto S.

J Neurosci. 2014 Jan 15;34(3):817-22. doi: 10.1523/JNEUROSCI.1703-13.2014.

11.

Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.

Costa A, Riedel M, Müller U, Möller HJ, Ettinger U.

Synapse. 2011 Oct;65(10):998-1005. doi: 10.1002/syn.20927. Epub 2011 Mar 28. Review.

PMID:
21404331
12.
13.

Pramipexole Impairs Stimulus-Response Learning in Healthy Young Adults.

Gallant H, Vo A, Seergobin KN, MacDonald PA.

Front Neurosci. 2016 Aug 19;10:374. doi: 10.3389/fnins.2016.00374. eCollection 2016.

14.

Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons.

Masi A, Narducci R, Resta F, Carbone C, Kobayashi K, Mannaioni G.

Eur J Neurosci. 2015 Nov;42(9):2699-706. doi: 10.1111/ejn.13066. Epub 2015 Oct 19.

PMID:
26354486
15.

Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon.

Blanchard V, Raisman-Vozari R, Vyas S, Michel PP, Javoy-Agid F, Uhl G, Agid Y.

Brain Res Mol Brain Res. 1994 Mar;22(1-4):29-38.

PMID:
7912404
16.

Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats.

Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T.

Auton Neurosci. 2002 Nov 29;102(1-2):30-8.

PMID:
12492133
17.

Transcriptional regulation by nicotine in dopaminergic neurons.

Henley BM, Williams BA, Srinivasan R, Cohen BN, Xiao C, Mackey ED, Wold BJ, Lester HA.

Biochem Pharmacol. 2013 Oct 15;86(8):1074-83. doi: 10.1016/j.bcp.2013.07.031. Epub 2013 Aug 9.

18.

Physiological properties of zebra finch ventral tegmental area and substantia nigra pars compacta neurons.

Gale SD, Perkel DJ.

J Neurophysiol. 2006 Nov;96(5):2295-306. Epub 2006 Jul 26.

19.

Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurons.

Keath JR, Iacoviello MP, Barrett LE, Mansvelder HD, McGehee DS.

J Neurophysiol. 2007 Dec;98(6):3388-96. Epub 2007 Oct 17.

20.

Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability.

Kasparbauer AM, Rujescu D, Riedel M, Pogarell O, Costa A, Meindl T, la Fougère C, Ettinger U.

Neuropsychopharmacology. 2015 Feb;40(3):736-45. doi: 10.1038/npp.2014.240. Epub 2014 Sep 15.

Supplemental Content

Support Center